GDGregory A. Dissen

Gregory A. Dissen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gregory A. Dissen has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Sergio Raul Ojeda

    Division of Neuroscience, Oregon National Primate Research Center/Oregon Health & Science University, Beaverton, OR 97006, USA

    8 shared publications
  • Sergio R. Ojeda

    Oregon Health & Science University

    4 shared publications
  • Alejandro Lomniczi

    Department of Physiology and Biophysics, Faculty of Medicine, Dalhousie University , Halifax, Nova Scotia

    3 shared publications
  • Artur Mayerhofer

    Cell Biology, Anatomy III, Biomedical Center Munich (BMC), LMU Medizin, Ludwig-Maximilians-Universität München , Planegg-Martinsried

    3 shared publications
  • Cecilia Garcia-Rudaz

    Division of Neuroscience, Oregon National Primate Research Center-Oregon Health and Science University, Beaverton, Oregon 97006, USA

    3 shared publications
  • Tanaya L. Neff

    Division of Neuroscience (G.A.D., A.L., T.L.N., S.H., S.R.O.), Oregon National Primate Research Center-Oregon Health and Science University, Beaverton, Oregon 97006-3448

    3 shared publications

Latest Publications

  • Open Access

    High-Throughput Screening for the Prevalence of Neutralizing Antibodies against Human Adenovirus Serotype 5

    by Jochen M. Wettengel, Hiroaki Naka, Gregory A. Dissen, Jeffrey Torgerson, Michelle Pounder, Simon F. Mueller, Elisabeth Mueller, Philipp Hagen, Micah Brandt, Ulrike Protzer, et al.

    Adenoviral vectors based on the human adenovirus species C serotype 5 (HAdV-C5) are commonly used for vector-based gene therapies and vaccines. In the preclinical stages of development, their safety and efficacy are often validated in suitable animal models. However, pre-existing neutralizing antibodies may severely influence study outcomes. Here, we generated a new HAdV-C5-based reporter vector and established a high-throughput screening assay for the multivalent detection of HAdV-C5-neutralizing antibodies in serum. We screened the sera of rhesus macaques at different primate centers, and of rabbits, horses, cats, and dogs, showing that HAdV-C5-neutralizing antibodies can be found in all species, albeit at different frequencies. Our results emphasize the need to prescreen model animals in HAdV-C5-based studies.


  • Early-in-life isoflurane exposure alters resting-state functional connectivity in juvenile non-human primates

    by Viola Neudecker, Jose F. Perez-Zoghbi, Oscar Miranda-Domínguez, Katie J. Schenning, Julian Sb. Ramirez, A.J. Mitchell, Anders Perrone, Eric Earl, Sam Carpenter, Lauren D. Martin, et al.


  • Open Access

    Novel WT1 Target Genes: IL-2, IL-2RB, and IL-2RG Discovered during WT1 Silencing Using Lentiviral‐Based RNAi in Myeloid Leukemia Cells

    by Duangnapa Dejjuy, Chavaboon Dechsukhum, Kovit Pattanapanyasat, Egarit Noulsri, Gregory A Dissen, Wilairat Leeanansaksiri

    Wilms’ tumor 1 (WT1) is a transcription factor which plays a major role in cell proliferation, differentiation, survival, and apoptosis. WT1 was first identified as a tumor suppressor gene in Wilms’ tumor. However, overexpression of WT1 has been detected in several types of malignancy including some types of leukemia. To investigate the molecular mechanism underlying WT1‐mediated leukemogenesis, lentiviral‐based siRNA was employed as a tool to suppress WT1 expression in the myeloid leukemia cell line, K562. Successfully, both WT1 RNA and protein levels were downregulated in the leukemia cells. The silencing of WT1 resulted in significant growth inhibition in WT1‐siRNA‐treated cells for 40 ± 7.0%, 44 ± 9.5%, and 88 ± 9.1% at 48, 72, and 96 hours posttransduction as compared with the control cells, respectively. By using apoptosis detection assays (caspase‐3/7 activity and Annexin V‐FITC/PI assays), WT1 silencing induced a higher degree of early and late apoptosis in siRNA‐treated K562 as compared with the control cells. Interestingly, the expression of survival signaling genes, IL-2, IL-2RB, and IL-2RG, was also suppressed after WT1‐siRNA treatment. In addition, the WT1 silencing also inhibited the S phase of the cell cycle and induced cell death. Our results indicated that WT1 silencing by siRNA can suppress cellular proliferation, induce apoptosis, and reduce S phase fraction of K562 cells. Moreover, transcriptional modulation of IL-2, IL-2RB, and IL2-2RG expression by WT1 was likely involved in this phenotypic change. Overall, this study confirmed the oncogenic role of WT1 in myeloid leukemia and discovered the new target genes of WT1 which are likely involved in WT1‐mediated leukemogenesis.


  • Isoflurane exposure leads to apoptosis of neurons and oligodendrocytes in 20- and 40-day old rhesus macaques

    by Katie J. Schenning, Kevin K. Noguchi, Lauren Drew Martin, Francesca M. Manzella, Omar H. Cabrera, Gregory A Dissen, Ansgar M. Brambrink


  • Open Access

    460. Very Low Prevalence of Circulating Antibodies Against Common AAV Serotypes in a Population of Cats

    by Kota Yoshida, Kei Adachi, Gregory A. Dissen, Alejandro Lomniczi, Sergio R. Ojeda, Hiroyuki Nakai

  • Open Access

    477. Three-Dimensional Imaging of Multiple AAV Serotype/Mutant Vector Transductions in the Non-Human Primate Brain By Massively Parallel Sequencing

    by Kei Adachi, Zheng Liu, Christopher D. Kroenke, Gregory A. Dissen, Sergio R. Ojeda, Hiroyuki Nakai

  • Open Access

    Expression of the beta-2 adrenergic receptor (ADRB-2) in human and monkey ovarian follicles: a marker of growing follicles?

    by Christoph Merz, Sabine Saller, Lars Kunz, Jing Xu, Richard R Yeoman, Alison Y Ting, Maralee S Lawson, Richard L Stouffer, Jon D Hennebold, Francis Pau, et al.

    ADRB-2 was implicated in rodent ovarian functions, including initial follicular growth. In contrast, ADRB-2 expression and function in nonhuman primate and human ovary were not fully known but innervation and significant levels of norepinephrine (NE), which is a ligand at the ADRB-2, were reported in the ovary. We studied expression of ADRB-2 in human and rhesus monkey ovary (RT-PCR, immunohistochemistry; laser micro dissection) and measured levels of norepinephrine (NE; ELISA) in monkey follicular fluid (FF). 3D cultures of monkey follicles (4 animals) were exposed to NE or the ADRB-2 agonist isoproterenol (ISO), and follicular development (size) was monitored. Upon termination expression of ADRB-2, FSH receptor and aromatase genes were examined. Immunohistochemistry and RT-PCR of either human follicular granulosa cells (GCs) obtained by laser micro dissection or isolated monkey follicles revealed ADRB-2 in GCs of primordial, primary, secondary and tertiary follicles. Staining of GCs in primordial and primary follicles was intense. In large preantral and antral follicles the staining was heterogeneous, with positive and negative GCs present but GCs lining the antrum of large follicles were generally strongly immunopositive. Theca, interstitial, and ovarian surface epithelial cells were also positive. NE was detected in FF of preovulatory antral monkey follicles (0.37 + 0.05 ng/ml; n = 7; ELISA) but not in serum. We examined preantral follicles ranging from 152 to 366 μm in diameter in a 3D culture in media supplemented with follicle stimulating hormone (FSH). Under these conditions, neither NE, nor ISO, influenced growth rate in a period lasting up to one month. Upon termination of the cultures, all surviving follicles expressed aromatase and FSH receptors, but only about half of them also co-expressed ADRB-2. The ADRB-2 expression was not correlated with the treatment but was positively correlated with the follicular size at the beginning and at the end of the culture period. Hence, expression of ADRB-2 was found in the largest and fastest-in vitro growing follicles. The results imply ADRB-2-mediated actions in the development of primate follicles. Drugs interfering with ADRB-2 are used to treat medical conditions and may have unexplored effects in the human ovary.


  • Open Access

    Hypothalamic EAP1 (Enhanced at Puberty 1) Is Required for Menstrual Cyclicity in Nonhuman Primates

    by Gregory A. Dissen, Alejandro Lomniczi, Sabine Heger, Tanaya L. Neff, Sergio R. Ojeda

    Mammalian reproductive cyclicity requires the periodic discharge of GnRH from hypothalamic neurons into the portal vessels connecting the neuroendocrine brain to the pituitary gland. GnRH secretion is, in turn, controlled by changes in neuronal and glial inputs to GnRH-producing neurons. The transcriptional control of this process is not well understood, but it appears to involve several genes. One of them, termed enhanced at puberty 1 (EAP1), has been postulated to function in the female hypothalamus as an upstream regulator of neuroendocrine reproductive function. RNA interference-mediated inhibition of EAP1 expression, targeted to the preoptic region, delays puberty and disrupts estrous cyclicity in rodents, suggesting that EAP1 is required for the normalcy of these events. Here, we show that knocking down EAP1 expression in a region of the medial basal hypothalamus that includes the arcuate nucleus, via lentiviral-mediated delivery of RNA interference, results in cessation of menstrual cyclicity in female rhesus monkeys undergoing regular menstrual cycles. Neither lentiviruses encoding an unrelated small interfering RNA nor the placement of viral particles carrying EAP1 small interfering RNA outside the medial basal hypothalamus-arcuate nucleus region affected menstrual cycles, indicating that region-specific expression of EAP1 in the hypothalamus is required for menstrual cyclicity in higher primates. The cellular mechanism by which EAP1 exerts this function is unknown, but the recent finding that EAP1 is an integral component of a powerful transcriptional-repressive complex suggests that EAP1 may control reproductive cyclicity by inhibiting downstream repressor genes involved in the neuroendocrine control of reproductive function.


  • Using Lentiviral Vectors as Delivery Vehicles for Gene Therapy

    by Gregory A. Dissen, Jodi McBride, Alejandro Lomniczi, Valerie Matagne, Mauricio Dorfman, Tanaya L. Neff, Francesco Galimi, Sergio R. Ojeda


  • Open Access

    Excessive ovarian production of nerve growth factor elicits granulosa cell apoptosis by setting in motion a tumor necrosis factor α/stathmin-mediated death signaling pathway

    by Cecilia Garcia-Rudaz, Mauricio Dorfman, Srinivasa Nagalla, Konstantin Svechnikov, Olle Söder, Sergio R Ojeda, Gregory A Dissen

    Excessive nerve growth factor (NGF) production by the ovary, achieved via a transgenic approach, results in arrested antral follicle growth, reduced ovulatory capacity, and a predisposition to cyst formation in response to mildly elevated LH levels. Two salient features in these mutant mice (termed 17NF) are an elevated production of 17α-hydroxyprogesterone (17-OHP4), testosterone, and estradiol (E2) in response to gonadotropins, and an increased frequency of granulosa cell (GC) apoptosis. In this study, we show that the increase in steroidal response is associated with enhanced expression of Cyp17a1, Hsd17b, and Cyp19a1, which encode the enzymes catalyzing the synthesis of 17-OHP4, testosterone, and E2 respectively. Using a proteomic approach, we identified stathmin (STMN1), as a protein that is overproduced in 17NF ovaries. In its phosphorylated state, STMN1 mediates a cell death signal initiated by tumor necrosis factor α (TNF). STMN1 is expressed in GCs and excessive NGF increases its abundance as well as that of its forms phosphorylated at serine (Ser) 16, 25, and 38. TNF synthesis is also increased in 17NF ovaries, and this change is abolished by blocking neurotrophic tyrosine kinase receptors. Inhibiting TNF actions in vivo by administering a soluble TNF receptor prevented the increase in total and phosphorylated STMN1 production, as well as GC apoptosis in NGF-overproducing ovaries. These results indicate that an excess of NGF in the ovary promotes steroidogenesis by enhancing the expression of enzyme genes involved in 17-OHP4, testosterone, and E2 synthesis, and causes GC apoptosis by activating a TNF/ STMN1-mediated cell death pathway. Abstract Excessive nerve growth factor (NGF) production by the ovary, achieved via a transgenic approach, results in arrested antral follicle growth, reduced ovulatory capacity, and a predisposition to cyst formation in response to mildly elevated LH levels. Two salient features in these mutant mice (termed 17NF) are an elevated production of 17α-hydroxyprogesterone (17-OHP4), testosterone, and estradiol (E2) in response to gonadotropins, and an increased frequency of granulosa cell (GC) apoptosis. In this study, we show that the increase in steroidal response is associated with enhanced expression of Cyp17a1, Hsd17b, and Cyp19a1, which encode the enzymes catalyzing the synthesis of 17-OHP4, testosterone, and E2 respectively. Using a proteomic approach, we identified stathmin (STMN1), as a protein that is overproduced in 17NF ovaries. In its phosphorylated state, STMN1 mediates a cell death signal initiated by tumor necrosis factor α (TNF). STMN1 is expressed in GCs and excessive NGF increases its abundance as well as that of its forms phosphorylated at serine (Ser) 16, 25, and 38. TNF synthesis is also increased in 17NF ovaries, and this change is abolished by blocking neurotrophic tyrosine kinase receptors. Inhibiting TNF actions in vivo by administering a soluble TNF receptor prevented the increase in total and phosphorylated STMN1 production, as well as GC apoptosis in NGF-overproducing ovaries. These results indicate that an excess of NGF in the ovary promotes steroidogenesis by enhancing the expression of enzyme genes involved in 17-OHP4, testosterone, and E2 synthesis, and causes GC apoptosis by activating a TNF/ STMN1-mediated cell death pathway.